Role of Inflammation in Depressive and Anxiety Disorders, Affect, and Cognition: Genetic and Non-Genetic Findings in the Lifelines Cohort Study.

Authors

Naoise Mac Giollabhui⁺, Depression Clinical & Research Program, Department of Psychiatry, Massachusetts General Hospital, USA.

Chloe Slaney⁺, MRC Integrative Epidemiology Unit at the University of Bristol, UK; Centre

for Academic Mental Health, Bristol Medical School, University of Bristol, Bristol, UK

Gibran Hemani, MRC Integrative Epidemiology Unit at the University of Bristol, UK

Éimear M. Foley, MRC Integrative Epidemiology Unit at the University of Bristol, UK;

Centre for Academic Mental Health, Bristol Medical School, University of Bristol, Bristol, UK.

Peter J. van der Most, University of Groningen, University Medical Center Groningen, the Netherlands.

Ilja M. Nolte, University of Groningen, University Medical Center Groningen, the Netherlands.

Harold Snieder, University of Groningen, University Medical Center Groningen, the Netherlands.

George Davey Smith, MRC Integrative Epidemiology Unit at the University of Bristol, UK. Golam Khandaker^{*}, MRC Integrative Epidemiology Unit at the University of Bristol, Bristol, UK; Centre for Academic Mental Health, Bristol Medical School, University of Bristol, Bristol,

RUNNING TITLE: INFLAMMATION, AFFECT, DEPRESSIVE AND ANXIETY DISORDERS AND COGNITIVE TASK PERFORMANCE

UK; NIHR Bristol Biomedical Research Centre, University Hospitals Bristol and Weston NHS Foundation Trust and University of Bristol, Bristol, UK; Avon and Wiltshire Mental Health Partnership NHS Trust, Bristol, UK.

Catharina A. Hartman^{*}, Interdisciplinary Center Psychopathology and Emotion Regulation, Department of Psychiatry, University Medical Center Groningen, University of Groningen, the Netherlands.

⁺ = Equally contributing first author.

^{*} = Equally contributing senior author.

Corresponding authors: Please direct correspondence regarding non-genetic analyses to Naoise Mac Giollabhui (Depression Clinical & Research Program, 1 Bowdoin Square, Massachusetts General Hospital, Boston, MA, USA. E-mail: <u>nmacgiollabhui@mgh.harvard.edu</u>) and correspondence regarding genetic analyses to Chloe Slaney (MRC Integrative Epidemiology Unit at the University of Bristol, Oakfield House, Oakfield Grove, Bristol BS8 2BN, UK. Email: <u>chloe.slaney@bristol.ac.uk</u>).

Word count (excluding abstract): 5,375

Keywords: Depression; Anxiety; Affect; Cognition; Inflammation; CRP; Lifelines Cohort; Mendelian randomization.

RUNNING TITLE: INFLAMMATION, AFFECT, DEPRESSIVE AND ANXIETY DISORDERS AND COGNITIVE TASK PERFORMANCE

1

Abstract

2 **Background:** Low-grade systemic inflammation is implicated in the pathogenesis of various 3 neuropsychiatric conditions affecting mood and cognition. While much of the evidence concerns 4 depression, large-scale population studies of anxiety, affect, and cognitive function are scarce. 5 Importantly, causality remains unclear. We used complementary non-genetic, genetic risk score 6 (GRS), and Mendelian randomization (MR) analyses to examine whether inflammatory markers 7 are associated with affect, depressive and anxiety disorders, and cognitive performance in the 8 Lifelines Cohort; and whether associations are likely to be causal. 9 Methods: Using data from up to 55,098 (59% female) individuals from the Dutch Lifelines 10 cohort, we tested the cross-sectional and longitudinal associations of C-reactive protein (CRP) 11 with (i) depressive and anxiety disorders; (ii) positive and negative affect scores, and (iii) five 12 cognitive measures assessing attention, psychomotor speed, episodic memory, and executive 13 functioning (figural fluency and working memory). Additionally, we examined the association 14 between inflammatory marker GRSs (CRP, interleukin-6 [IL-6], IL-6 receptor [IL-6R and 15 soluble IL-6R (sIL-6R)], glycoprotein acetyls [GlycA]) on these same outcomes (N_{max}=57,946), 16 followed by MR analysis examining evidence of causality of CRP on outcomes (N_{max}=23,268). 17 In genetic analyses, all GRSs and outcomes were z-transformed.

18 **Results:** In non-genetic analyses, higher CRP was associated with diagnosis of any 19 depressive disorder, lower positive and higher negative affect scores, and worse performance on 20 tests of figural fluency, attention, and psychomotor speed after adjusting for potential 21 confounders, although the magnitude of these associations was small. In genetic analyses, 22 CRP_{GRS} was associated with any anxiety disorder (β =0.002, *p*=0.037, N=57,047) whereas 23 GlycA_{GRS} was associated with major depressive disorder (β =0.001, *p*=0.036; N=57,047). Both

RUNNING TITLE: INFLAMMATION, AFFECT, DEPRESSIVE AND ANXIETY DISORDERS AND COGNITIVE TASK PERFORMANCE

24	CRP_{GRS} (β =0.006, p =0.035, N=57,946) and GlycA _{GRS} (β =0.006, p =0.049; N=57,946) were
25	associated with higher negative affect score. Inflammatory marker GRSs were not associated
26	with cognitive performance, except sIL- $6R_{GRS}$ which was associated with poorer memory
27	performance (β =-0.009, <i>p</i> =0.018, N=36,783). Further examination of the CRP-anxiety
28	association using MR provided some weak evidence of causality (β =0.12; p=0.054).
29	Conclusions: Genetic and non-genetic analyses provide consistent evidence for an
30	association between CRP and negative affect. Genetic analyses suggest that IL-6 signaling could
30 31	association between CRP and negative affect. Genetic analyses suggest that IL-6 signaling could be relevant for memory, and that the association between CRP and anxiety disorders could be
31	be relevant for memory, and that the association between CRP and anxiety disorders could be
31 32	be relevant for memory, and that the association between CRP and anxiety disorders could be causal. These results suggest that dysregulated immune physiology may impact a broad range of

RUNNING TITLE: INFLAMMATION, AFFECT, DEPRESSIVE AND ANXIETY DISORDERS AND COGNITIVE TASK PERFORMANCE

0	7
.)	1
\sim	

1. Introduction

38	Depression affects 300 million individuals worldwide at any given point in time and is the
39	leading cause of mental health-related global disease burden (1-3). Persistent cognitive problems,
40	such as poor memory and concentration, are reported in 11% of adults aged \geq 45 years (4) and are
41	frequently observed across a broad range of physical [cancer (35%); COVID-19 (22%); HIV
42	(43%); hepatitis C (50%)] (5-8) and mental health conditions [depression (30%); schizophrenia
43	(50%)] (9, 10). Existing treatments for depression are only modestly effective (11) and almost
44	inexistent for cognitive dysfunction (12, 13). A mechanistic understanding of depression and
45	cognitive dysfunction is urgently needed to inform the development of effective treatments and
46	prevention approaches.
47	Chronic, low-grade systemic inflammation may represent one such mechanism. Indices of
48	inflammation [e.g., circulating levels of cytokines (e.g., interleukin-6 (IL-6) and acute phase
49	proteins (e.g., C-reactive protein (CRP)] are elevated in individuals with depression compared to
50	controls (14) and inflammatory biomarkers have been linked to specific aspects of depression,
51	such as anhedonia and negative affect (15-17). Further, longitudinal observational studies have
52	found that higher levels of inflammatory biomarkers (e.g., IL-6, CRP) are prospectively
53	associated with higher depressive symptoms (18). Observational studies have linked
54	inflammation with impaired cognition in population-based (19-22) and in physical (5-9, 23-27)
55	and mental health conditions (28-32). Inflammation also impacts neural circuitry relevant to
56	affective disorder and cognitive task performance (33, 34), particularly the hippocampus (35)
57	and striatum (36-39). To date, inflammation-cognition research has primarily relied upon
58	observational data.

RUNNING TITLE: INFLAMMATION, AFFECT, DEPRESSIVE AND ANXIETY DISORDERS AND COGNITIVE TASK PERFORMANCE

59 Inferring causality from observational studies is a challenge due to confounding (e.g., stress, 60 poor sleep (27)) and reverse causality (i.e., whether inflammation impacts depression/cognition, 61 or vice versa). Mendelian randomization (MR) is a genetic epidemiological method that can test 62 causal relationships by using genetic variants associated with an exposure (e.g., inflammation) as 63 proxies for the exposure (40, 41). As genetic variants are randomly inherited from parents to 64 offspring and are fixed at conception, they are less likely to be associated with confounders and 65 overcome issues of reverse causation (40, 41). Preliminary evidence, using MR, implicate IL-6 66 and its soluble IL-6 receptor (sIL-6R) in depression (42-45). To date, most MR studies 67 examining the effect of IL-6 on health have focused on circulating IL-6 levels. However, IL-6 68 signals via multiple pathways (trans-signaling, classical-signaling, and trans-presentation) and 69 there is growing evidence that IL-6 trans-signaling is primarily responsible for the pathogenic 70 inflammatory effects of IL-6 (46, 47). Here, we include variants related to (1) circulating IL-6 71 levels, and (2) sIL-6R levels (relevant for IL-6 trans-signaling). Causal evidence for CRP and 72 other proinflammatory markers [i.e., Glycoprotein Acetyls (GlycA) a composite biomarker 73 thought to provide a more stable marker of inflammation which reflects the glycosylation of 74 multiple acute-phase proteins (48-51)] on depression are mixed (42, 45, 52-55). Regarding 75 cognition, few studies have examined potential causal relationships with inflammation. MR 76 analyses using available genome-wide association studies (GWAS) report both null results of 77 inflammatory biomarkers on emotion recognition, working memory, response inhibition (56) as 78 well as effects of specific cytokines/chemokines (i.e., Eotaxin, IL-8, MCP1, IL-4) on fluid 79 intelligence (57).

80 The current study used data from the Lifelines Cohort Study – a large population-based
81 cohort in the Netherlands – to conduct complementary non-genetic and genetic analysis to

RUNNING TITLE: INFLAMMATION, AFFECT, DEPRESSIVE AND ANXIETY DISORDERS AND COGNITIVE TASK PERFORMANCE

- 82 investigative the causal relationship between inflammation and negative affect, depressive
- 83 disorders, and cognitive task performance. First, we used cross-sectional and longitudinal non-
- 84 genetic analysis examine the association between circulating levels of CRP and
- 85 depression/cognitive performance. Second, we conducted genetic risk score (GRS) and MR
- 86 analysis to test whether genetic variants regulating levels and activity of CRP, IL-6, and GlycA
- 87 were causally related with depression/cognitive performance. We also conducted the above
- 88 analyses on closely related constructs (e.g., anxiety, negative/positive affect), for which
- 89 associations with inflammation have previously been observed (58-63) but for which
- 90 considerably less empirical data has been published. We hypothesized that both circulating CRP
- 91 levels and genetically predicted inflammatory biomarkers (i.e., CRP, IL-6, sIL-6R, and GlycA)
- 92 would be associated with depression, cognitive task performance, affect, and anxiety.

RUNNING TITLE: INFLAMMATION, AFFECT, DEPRESSIVE AND ANXIETY DISORDERS AND COGNITIVE TASK PERFORMANCE

94

2. Methods and Materials

95 **2.1 Participants**

96 Lifelines is a multi-disciplinary prospective population-based cohort study examining in a 97 unique three-generation design the health and health-related behaviors of 167,729 persons living 98 in the North of the Netherlands. It employs a broad range of investigative procedures in assessing 99 the biomedical, socio-demographic, behavioral, physical and psychological factors which 100 contribute to the health and disease of the general population, with a special focus on multi-101 morbidity and complex genetics (64). This cohort has previously been described in detail (64, 102 65). In brief, participants were recruited via their general practitioner (49%), participating family 103 members (38%), and self-registration on the Lifelines website (13%). Exclusion criteria for 104 recruitment through the general practitioner included: insufficient knowledge of Dutch language, 105 severe psychiatric or physical illness, limited life expectancy (<5 years). Baseline data included 106 approximately: 140,000 adults (18-65 years), 15,000 children (0-17 years), 12,000 elderly 107 individuals (65+ years). Following baseline assessment, participants are invited to complete an in-person study visit every 5 years (2nd in person follow-up assessment just finished end of 108 2023). Phenotypic and genotypic data are collected by Lifelines to permit investigation on 109 110 determinants of health. Data for the current study were drawn from 147,815 individuals who 111 were aged 18+ years at baseline and who did not report a diagnosis that typically impairs 112 cognitive function, specifically Alzheimer's disease, other dementias, epilepsy, multiple 113 sclerosis, Parkinson's disease, and stroke. In the non-genetic analyses, the analytic sample is 114 smaller as CRP was assessed in a sub-sample of individuals (N=55,098) as was baseline 115 cognitive performance on the Ruff Figural Fluency Test (N=88,096). The analytic sample is 116 smaller for non-genetic (N≤55,098), GRS (N≤57,946) and MR (N≤23,268) analysis as only a

RUNNING TITLE: INFLAMMATION, AFFECT, DEPRESSIVE AND ANXIETY DISORDERS AND COGNITIVE TASK PERFORMANCE

117 subset of participants who met inclusion criteria had outcome data and (i) CRP data (non-genetic

analysis), (ii) genetic data (GRS), or (iii) genetic and CRP data (MR) due to time and cost

119 constraints. Phenotypic data were drawn from both the baseline assessment and the first follow-

120 up assessment; whether a specific measure was assessed at baseline, first follow-up or both

121 assessments is noted for each measure.

122 **2.2 Measures**

123 2.2.1 Measures of Cognitive Task Performance

124 *Ruff Figural Fluency Test (baseline in-person assessment).* The Ruff Figural Fluency Test

125 (RFFT) is a reliable and valid measure of figural fluency, a dimension of executive function (66),

126 measured at the baseline assessment. It is likely that performance on the RFFT also depends on

127 other cognitive abilities, such as processing speed (67, 68). Participants were asked to draw as

128 many unique designs as possible within 60 seconds by connecting dots in different patterns. The

129 task is composed of five parts, with each part containing 35 identical five-dot patterns (with or

130 without distractors). The total number of unique designs was used as the dependent variable in

131 the analyses, consistent with previous studies (69, 70). In Lifelines, the RFFT was administered

to all participants until April 2012, and subsequently in a random half of the sample. Data from

participants who failed to generate a single unique design per trial (n = 181) were deemed invalid and removed.

Cogstate Test Battery (first follow-up in-person assessment). Assessments included in the
Cogstate Test Battery consisted of four tasks and took approximately 10-15 minutes to complete.
Each task was designed to tap into specific cognitive domains: detection task (psychomotor
speed), identification task (attention), one-back task (working memory), and one card learning

RUNNING TITLE: INFLAMMATION, AFFECT, DEPRESSIVE AND ANXIETY DISORDERS AND COGNITIVE TASK PERFORMANCE

139	task (episodic memory), although, like in the RFFT, processing speed likely plays a role in all
140	tasks. For each task, outcomes recommended by Cogstate were selected, specifically: log10
141	transformed response time in millisecond (detection and identification tasks) and arcsine-
142	transformed response accuracy (one-back and one card learning tasks). For the detection and
143	identification tasks, higher values reflect poorer performance and for the one-back and one card
144	learning tasks, higher values equal better performance. Data cleaning involved excluding
145	participants with a high number of errors. The percentage of successful trials per Cogstate task
146	was high, averaging 66% ($n = 85,050$; $SD = .11$) on the episodic memory task, 91% ($n = 85,053$;
147	SD = .17) on the visual attention task, 92% ($n = 85,053$; $SD = .20$) on the psychomotor speed
148	task, and 90% ($n = 85,051$; $SD = .15$) on the working memory task. A small number of
149	participants exhibiting implausibly low accuracy rates indicative of poor effort, failure to
150	comprehend task instructions, or technical errors were excluded from analyses. Specifically
151	individuals with an accuracy rate less than: 25% on the episodic memory task ($n = 231$), 40% on
152	the visual attention task ($n = 2,878$), 45% on the psychomotor speed task ($n = 3,914$), and 35%
153	on the working memory task ($n = 1,330$). For more details on the Cogstate Test Battery, see
154	Supplementary Methods 1.1.

155 2.2.2 Clinical Assessments

Anxiety and Depressive Disorders (baseline and first follow-up in-person assessments). The Mini International Neuropsychiatric Interview – Simplified (MINI) is a reliable, valid, and brief structured interview that was designed to screen for psychiatric disorders (71-73). Lifelines used an adapted version of a Dutch translation of the MINI that was administered by trained interviewers at baseline and self-administered on location at follow-up – details on the version used in Lifelines have previously been published (74). Participants were considered to meet

RUNNING TITLE: INFLAMMATION, AFFECT, DEPRESSIVE AND ANXIETY DISORDERS AND COGNITIVE TASK PERFORMANCE

162 criteria for any depressive disorder if they met the Diagnostic and Statistical Manual of Mental 163 Disorders (DSM)-IV criteria for Major Depressive Disorder (MDD) or dysthymia at the time of 164 the interview. Impairment was assessed in the MINI for dysthymia but not depression and 165 consequently, impairment was not used as a criterion for MDD. Any anxiety disorder refers to 166 meeting current criteria for any one of the following conditions that was assessed using the MINI: panic disorder, agoraphobia, social phobia, or Generalized Anxiety Disorder (GAD). We 167 168 used four diagnostic groups as outcome variables: MDD, any depressive disorder, GAD, and any 169 anxiety disorder.

170 *Positive and Negative Affect Schedule (baseline in-person assessment).* The Positive and

Negative Affect Schedule (PANAS) is composed of two subscales which are designed to assess
positive and negative affect (75). Each subscale has 10 items (examples of items include
'excited' on positive subscale; 'upset' on negative subscale). Participants are asked to rate the
extent that they experienced each item during the last four weeks on a five-point scale (ranging
from 'not at all' to 'extremely'). The outcome is the summed score on each subscale, which
ranges from 10 to 50 (higher value reflects higher positive or negative affect, respectively). The
PANAS has been shown to be reliable and valid (76).

178 2.2.3 C-reactive Protein (baseline in-person assessment)

Participants gave blood samples before 10AM via venipuncture following an overnight fast. Complete details on blood specimen data collection have previously been reported (64, 70). Due to assay costs, CRP was assessed in approximately 35% of Lifelines participants and data were available for 55,098 individuals in the analytic sample. CRP was quantified using three separate methods over the course of baseline assessment (Method 1: 12.90% of total CRP values assessed in serum; CardioPhase hsCRP; Method 2: 84.58% of total CRP values, assessed in plasma;

RUNNING TITLE: INFLAMMATION, AFFECT, DEPRESSIVE AND ANXIETY DISORDERS AND COGNITIVE TASK PERFORMANCE

- 185 CardioPhase high sensitivity (hs)CRP, Siemens Healthcare Diagnostics, Marburg, Germany;
- 186 Method 3: 2.52% of total CRP values; assessed in plasma; CRPL3, Roche Diagnostics,
- 187 Mannheim, Germany). Assay methods 2 and 3 were identical and only differed in terms of the
- 188 manufacturer. A conversion formula (new = 0.92×0.01) was derived from an internal
- 189 validation using 39 samples, according to the AMC (alternative method comparison, Deming
- 190 Regression) protocol in order that Method 1 could be compared with Method 2 and 3 (70). For
- 191 CardioPhase hsCRP, the intra-assay coefficient of variability was 3.45% and the inter-assay
- 192 coefficient of variability was 3.15%. For CRPL3, the intra-assay coefficient of variability was
- 193 4.15% and the inter-assay coefficient of variability was 5.8%.
- 194 2.2.4 Genetic Data

195 Genotype data were available for a subgroup of participants in Lifelines. Genotyping was

196 conducted using three chip arrays: (i) Illumina CytoSNP-12 Bead Chip v2 array (N=17,033), (ii)

197 Infinium Global Screening Array (GSA) Beadchip-24 v1.0 (N=38,030), (iii) FinnGen Thermo

198 Fisher Axiom ® custom array (Affymetrix; N=29,166). For details on quality checks (QC's) and

199 imputation conducted by Lifelines, see Supplementary Methods 1.2. Following Lifelines QC's,

200 the total sample size for participants who met criteria for this study: CytoSNP (N=14,942), GSA

201 (N=31,810) and Affymetrix (N=26,334). We applied additional QC's which included removing:

202 (i) one of the duplicates (individuals who were genotyped on more than one chip) and first-

203 degree relatives between chips, (ii) non-European individuals (identified by Lifelines), and (iii)

204 genetic outliers (identified by Lifelines); see Supplementary Figure 1 for more details. This

205 resulted in a total of 58,713 participants with genetics data included in this study (CytoSNP

206 N=7,632; GSA N=24,975; Affymetrix N=26,106). For more details on the genetic data in

207 Lifelines, see Supplementary Methods 1.2.

RUNNING TITLE: INFLAMMATION, AFFECT, DEPRESSIVE AND ANXIETY DISORDERS AND COGNITIVE TASK PERFORMANCE

208 *2.2.5 Covariates*

209	Covariates included age, sex, educational attainment, body mass index (BMI) and health
210	status. Age, sex, and educational attainment were self-reported by participants. Educational
211	attainment was determined using a single-item question and was categorized by Lifelines as: low
212	[no education, primary education, lower/preparatory vocational education, lower general
213	secondary education (leaving secondary school aged >16 years)], moderate (intermediate
214	vocational education/apprenticeship, higher secondary education), and high (higher vocational
215	education, university). We recoded educational attainment so that higher values represent lower
216	educational attainment. To estimate body mass index (BMI), height was measured to the closest
217	0.1 cm and body weight was measured without shoes to 0.1 kg precision. For health status, a
218	composite measure was created counting several self-reported chronic medical conditions related
219	to increased levels of inflammation (i.e., arthritis, asthma, coeliac disease, Crohn's disease,
220	diabetes, and psoriasis); we then categorized participants into those with no relevant chronic
221	medical condition, 1, 2 or 3+ conditions.

222 **2.3 Analyses**

Analyses were conducted in R version 4.1.1.(77)

224 2.3.1 Non-genetic Analyses

225 Multivariable linear and logistic regression models were estimated using base functions in R

(i.e., 'lm', 'glm'). CRP was transformed by natural log to impose a normal distribution.

- 227 2.3.2 Genetic Risk Scores
- 228 Genetic risk scores (GRS) were calculated to determine whether GRS for inflammatory
- 229 markers (CRP, IL-6, IL-6R, sIL-6R, GlycA) were associated with depression/anxiety, affect and

RUNNING TITLE: INFLAMMATION, AFFECT, DEPRESSIVE AND ANXIETY DISORDERS AND COGNITIVE TASK PERFORMANCE

230 cognitive outcomes. To create GRS for each inflammatory marker, we identified genetic variants 231 (single nucleotide polymorphisms [SNPs]) associated with these proteins in large available 232 GWAS or using SNP lists from previous publications, see Table 1. For details on the GWAS 233 used and accessing summary statistics, please see Supplementary Methods 1.3 and 234 Supplementary Tables 1-2. The following criteria were used to identify SNPs from GWAS for each inflammatory marker: (i) p-value $< 5 \times 10^{-8}$, (ii) linkage disequilibrium clumping ($r^2=0.01$, 235 236 kb=1000 based on the European-clustering individuals in the 1000 genomes reference panel) 237 using *ld clump()* (78) in the *ieugwasr* package, (iii) minor allele frequency > 0.01. In the primary 238 analysis, we restricted the SNP set to *cis* variants (SNPs +/- 1Mb from protein coding gene based 239 on Genome Reference Consortium Human Build used in the GWAS) (79-84). The reason for 240 restricting to *cis* variants in the primary analysis is because, due to their proximity to the protein 241 coding gene, they are more likely to be valid instruments, as they are more likely to influence 242 mRNA expression and protein levels (thus being less pleiotropic) (85). For GlycA, which does 243 not have a single coding gene due to its composite nature, we used the largest available GWAS 244 in our primary analysis. In our secondary analyses, we used both *cis* and *trans* variants from 245 GWAS (i.e., we did not restrict to *cis* variants). Each SNP list (Table 1) was used to create a 246 weighted GRS for each Lifelines participant. Specifically, the risk alleles were weighted by the 247 effect size (beta) reported in the GWAS/previous study and then summed to provide a risk score. 248 Any SNP identified in GWAS/previous study that was not available in Lifelines was replaced with a proxy (where possible) that had $r^2 > 0.8$ (using *LDproxy_batch* function in EUR) 249 250 population in R), rsID (SNP name) available, SNP available in full summary statistic GWAS, 251 and in Lifelines (86, 87). GRS were created in Plink v1.90 (88) and continuous phenotypes were 252 standardized within each chip (z-scored) for direct comparison (CRP levels were log transformed

RUNNING TITLE: INFLAMMATION, AFFECT, DEPRESSIVE AND ANXIETY DISORDERS AND COGNITIVE TASK PERFORMANCE

but not standardized).

254 To adjust for relatedness within each chip, two approaches were taken. The primary approach 255 applied the GRAMMAR method (89) and the secondary approach involved re-running analyses 256 removing close relatives (up to first-degree, up to second-degree, and up to third-degree), see 257 Supplementary Materials 1.4 and 1.5 for details on how we identified close relatives. We then ran regression models predicting each outcome using the standardized GRS, including top 10 258 259 genetic PCs (calculated on merged Lifelines genotype data), age, sex, and chip. Maximum 260 sample size for analyses: no relatives within chips removed (N=58,713), up to first-degree 261 removed (N=50,955), up to second-degree removed (N=50,255), up to third-degree removed 262 (N=48,880). Unadjusted analyses are also reported in the Supplementary Tables 5 and 6 for 263 comparison.

264 2.3.3 Mendelian randomization

265 To conduct MR using individual level data and two-stage least squares regression, genetic 266 data, exposure data, and outcome data are required. As only CRP is available within the Lifelines 267 cohort (IL-6 and GlycA are not currently available), only this inflammatory marker could be 268 assessed in the MR analysis. Where there was evidence of associations between CRP GRS and 269 outcomes, we followed this up with MR to assess potential causality. Three key assumptions are 270 necessary for valid inferences from MR: (i) genetic variants are robustly associated with the 271 exposure, (ii) genetic variants are not associated with potential confounders, (iii) genetic variants 272 are associated with the outcome only via the exposure. Two-stage least squares regressions were 273 conducted using the AER package (90). Analyses were GRAMMAR adjusted for relatedness and 274 all regression models adjusted for age, sex, and chip. To check MR assumptions, we ran linear 275 regressions to test whether CRP GRS were associated with circulating CRP levels in participants

RUNNING TITLE: INFLAMMATION, AFFECT, DEPRESSIVE AND ANXIETY DISORDERS AND COGNITIVE TASK PERFORMANCE

- with both genetic and CRP data available (n = 23,607) using the GRAMMAR method. We also
- 277 checked whether any inflammatory marker GRS (CRP, IL-6, IL-6R, sIL-6R, GlycA) were
- associated with potential confounders (BMI, current smoking status, educational attainment; all
- 279 models were adjusted for age, sex, and chip).

RUNNING TITLE: INFLAMMATION, AFFECT, DEPRESSIVE AND ANXIETY DISORDERS AND COGNITIVE TASK PERFORMANCE

281	3. Results
282	The characteristics of the Lifelines cohort sample are described in Table 2 and Pearson
283	correlations between study variables are presented in Table 3.
284	3.1 Association of CRP with affect, depressive and anxiety disorders, and cognitive task
285	performance
286	The association of (log-transformed) CRP with: (i) clinical outcomes (i.e., MDD, any
287	depressive disorder, GAD, any anxiety disorder), (ii) positive and negative affect, and (iii) five
288	cognitive measures [RFFT (executive functioning), detection task (psychomotor speed),
289	identification task (attention), one-back task (working memory), and one card learning task
290	(episodic memory)] are illustrated in Table 4, both unadjusted and adjusted for covariates.
291	Notably, CRP was associated with a greater likelihood of meeting criteria for a range of clinical
292	outcomes, with a numerically greater likelihood consistently reported for depression as compared
293	to anxiety at baseline and first follow-up assessment. However, these associations were
294	attenuated after controlling for confounding by age, sex, education, health status, and BMI.
295	Higher CRP was also associated with higher negative affect, lower positive affect, and worse
296	cognitive task performance, although the magnitude of associations was generally very small and
297	negligible after controlling for covariates.
298	3.2 Associations of GRSs for inflammatory markers with affect, depressive and anxiety
299	disorders
300	In the primary analysis, CRP_{GRS} (<i>cis</i>) was associated with a higher negative affect score
301	(beta: 0.006; 95% CI: 0.0005 to 0.012, p=0.035, N=57,946) and increased risk of any anxiety
302	disorder (beta: 0.002, 95% CI: 0.0001 to 0.004, p=0.037, N=57,047). GlycA _{GRS} was associated

RUNNING TITLE: INFLAMMATION, AFFECT, DEPRESSIVE AND ANXIETY DISORDERS AND COGNITIVE TASK PERFORMANCE

315	3.3 Association of GRS for inflammatory markers and cognitive task performance
314	0.015) and between CRP _{GRS} (<i>cis</i>) and negative affect score ($ps \le 0.033$).
313	slightly stronger evidence for associations between GlycA _{GRS} and negative affect score ($ps \le$
312	method) did not substantially alter results, see Supplementary Tables 7-12. Although, there was
311	individuals (up to 1 st -degree, up to 2 nd -degree, up to 3 rd -degree) within chips (non-GRAMMAR
310	1 and Supplementary Table 4. All sensitivity analyses removing differing degrees of related
309	were associated with depressive/anxiety disorders or affect ($ps \ge 0.16$). For all results, see Figure
308	0.004, $p=0.023$, N=57,047). There was little evidence that other inflammatory marker GRSs
307	was associated with increased risk of any anxiety disorders (beta: 0.002, 95% CI: 0.0003 to
306	scores ($ps \ge 0.15$). In the secondary analysis, there was evidence that CRP _{GRS} (<i>genome-wide</i>)
305	inflammatory marker GRSs were not associated with depressive/anxiety disorders or affect
304	and increased risk of MDD (beta: 0.001, 95% CI: 0.0001 to 0.002; p=0.036; N=57,047). Other
303	with higher negative affect score (beta: 0.006, 95% CI: 0.00002 to 0.012, p=0.049; N=57,946)

B ŀ

316 In primary analyses, inflammatory marker GRSs were not associated with performance on 317 cognitive tasks ($ps \ge 0.14$), except for sIL-6R_{GRS} which was negatively associated with episodic 318 memory performance (one card learning task accuracy; beta: -0.009, 95% CI: -0.017 to -0.002, 319 p=0.018, N=36,783), see Figure 2 and Supplementary Table 4. In secondary analyses, 320 inflammatory markers GRSs (genome-wide) were not associated with performance on cognitive 321 tasks ($ps \ge 0.22$). For all results, see Figure 2 and Supplementary Table 4. Sensitivity analyses 322 after removing related individuals within chips (non-GRAMMAR method) did not alter the 323 results, see Supplementary Tables 10-12.

324 3.4 Testing potential causality between CRP, negative affect, and anxiety disorders

RUNNING TITLE: INFLAMMATION, AFFECT, DEPRESSIVE AND ANXIETY DISORDERS AND COGNITIVE TASK PERFORMANCE

325 using Mendelian randomization with individual level data

- 326 CRP genetic instruments had F-statistics > 10 (158 for *cis* GRS, 1045 for *genome-wide*
- 327 GRS), indicating adequate instrument strength (91). For tests on the MR assumptions, see
- 328 Supplementary Results 2.2. There was weak evidence that genetically-proxied CRP (*cis*)
- 329 causally increased the risk of any anxiety disorders (beta: 0.12, *p*=0.054, N=22,154), and little
- evidence on negative affect (beta: 0.27, *p*=0.16; N=23,268). Sensitivity analysis removing
- 331 related individuals did not alter overall conclusions.
- 332 The overall pattern of results for the non-genetic and genetic analyses are visualized in
- 333 Figure 3.

RUNNING TITLE: INFLAMMATION, AFFECT, DEPRESSIVE AND ANXIETY DISORDERS AND COGNITIVE TASK PERFORMANCE

γ	25	٢.
Э	5.5	
-		

4. Discussion

336 We conducted complementary non-genetic and genetic analyses to interrogate the 337 relationship between inflammatory markers and affect, depressive and anxiety disorders, and 338 cognitive task performance using data from the Lifelines cohort. In non-genetic analyses, higher 339 CRP was associated with diagnosis of any depressive disorder, positive and negative affect 340 scores, figural fluency, attention, and psychomotor speed after adjusting for potential 341 confounders, although the magnitude of these associations was generally small. In genetic 342 analyses, genetic risk scores for CRP (CRP_{GRS}) and GlycA_{GRS} were both associated with higher 343 negative affect score. CRP_{GRS} was associated with any anxiety disorder whereas $GlycA_{GRS}$ was 344 associated with major depressive disorder. Inflammatory marker GRSs were not associated with 345 cognitive task performance, except for soluble IL-6R_{GRS} which was associated with poorer 346 memory performance. Individual level MR provided weak evidence for a causal effect of CRP 347 on any anxiety disorder. Genetic and non-genetic analyses provided consistent evidence for an 348 association, albeit small, of CRP on negative affect. Genetic analyses suggest that IL-6 signaling 349 could be relevant for memory, and that the association between CRP and anxiety disorders could 350 be potentially causal.

4.1 Affect

Prior studies have generally found inflammation to be associated with higher levels of negative affect and lower levels of positive affect, although findings are primarily based on medical populations (92-94) and small community samples (15, 95, 96). To our knowledge, this is the first large, population-based study to find small but consistent associations of higher CRP with higher negative affect and lower positive affect, both unadjusted and adjusted for age, sex, education, health status and BMI. Interestingly, both CRP and GlycA genetic risk scores were

RUNNING TITLE: INFLAMMATION, AFFECT, DEPRESSIVE AND ANXIETY DISORDERS AND COGNITIVE TASK PERFORMANCE

358 associated with higher levels of negative affect, but not positive affect. This consistent 359 association across non-genetic and genetic analyses may reflect the effect of inflammation on a 360 range of emotional states beyond the cardinal features of depression (i.e., sadness/anhedonia). 361 which aligns with prior research linking inflammation with fear and irritability (63, 97). Prior 362 work has shown that inflammation is differentially associated with a specific clinical 363 presentation characterized by anhedonia and somatic/neurovegetative symptoms (e.g., fatigue, 364 altered sleep and appetite changes) and further work is needed that more accurately characterize 365 an inflammatory phenotype in depression (98, 99).

366 **4.2 Depression**

367 These data add to a growing body of evidence evaluating the role of inflammation as 368 measured by circulating CRP levels in the etiology of depression. The results of non-genetic 369 analyses broadly aligns with results from the UK Biobank cohort in terms of (i) prevalence 370 estimates of depression and anxiety, (ii) robust univariate associations between CRP and 371 depression and anxiety, which were generally no longer statistically significant when controlling 372 for covariates, and (iii) stronger univariate associations for CRP and depression when compared 373 to anxiety (45). It has long been noted that variables being conceptualized as confounds that require statistical adjustment (e.g., BMI, medical illness) may, in fact, be key mechanisms in the 374 375 pathophysiology of inflammatory depression (100, 101). As such, attenuation of associations 376 following adjustment for covariates would not, by itself, indicate a non-causal relationship. 377 Indeed, inflammation may increase risk for depression via increasing the risk of inflammation-378 related physical multimorbidity (e.g., cardiovascular disease) (42) – a hypothesis that requires 379 further investigation.

RUNNING TITLE: INFLAMMATION, AFFECT, DEPRESSIVE AND ANXIETY DISORDERS AND COGNITIVE TASK PERFORMANCE

380 In genetic analyses, there was also little evidence of an association between CRP_{GRS} and 381 depression outcomes, although there was evidence suggesting GlycA_{GRS} increases liability to 382 MDD. The null CRP findings are consistent with previous MR studies showing no evidence of 383 effect in MDD (54, 55, 102). However, the MR literature of CRP on depression is mixed with 384 some studies reporting CRP to decrease (45) or increase (42) risk for depression. It is unclear 385 what accounts for these mixed findings, but potential factors may include CRP SNP selection, 386 definition and/or measurement of depression, statistical power, and selection bias (see 387 Supplementary Discussion). In contrast, MR studies have shown more consistent findings for the 388 potential causal role of IL-6 on depression (43-45, 103). This is similar to MR findings for 389 coronary heart disease, where IL-6 but not CRP have been shown to play a potential causal role 390 (104, 105). Consequently, studies on a broader range of immune markers (e.g. cytokines, 391 immune cells) and specific immune pathways would be more useful to understand the role of 392 inflammation in depression, rather than CRP which is a non-specific marker of systemic immune 393 activation (106).

394

4.3 Cognitive Task Performance

395 We observed relatively small effects of CRP on cognitive task performance, and in genetic 396 analysis only sIL-6R_{GRS} was associated with poor memory performance out of all inflammatory 397 markers and cognitive tasks examined. Our findings contribute to inconsistent findings across 398 population-based cohorts assessing circulating inflammatory biomarkers and cognitive 399 performance where associations observed in population-based studies (22, 30, 107) often are not 400 large in magnitude or consistently observed (56). Few MR studies have been conducted on the 401 role of inflammation on cognition. Consistent with results presented here, our previous MR study 402 examining the role of the same inflammatory markers (i.e., CRP, IL-6, IL-6R, sIL-6R, GlycA)

RUNNING TITLE: INFLAMMATION, AFFECT, DEPRESSIVE AND ANXIETY DISORDERS AND COGNITIVE TASK PERFORMANCE

403	on specific executive functions within the ALSPAC cohort (e.g., emotion recognition, working
404	memory, response inhibition (56)) found little evidence of a potential causal effect. However,
405	Pagoni et al. recently reported that other cytokines and chemokines (i.e., Eotaxin , IL-8, MCP1)
406	may be causally related to lower fluid intelligence (and IL-4 with higher fluid intelligence) (57).
407	The finding regarding sIL-6R and memory performance is novel and would align with
408	convergent evidence that trans-signaling – in which sIL-6R plays a critical role – may be
409	responsible for the deleterious effect of IL-6 on cognitive functioning (47, 108).
410	Interpreting the relationship between inflammation and cognitive task performance in
411	population-based studies is difficult for several reasons. First, there is considerable heterogeneity
412	in the type and breadth of cognitive abilities assessed across studies and there is a need for future
413	studies to more uniformly include well-validated measures assessing individual differences
414	[rather than detecting pathological states (e.g., dementia, epilepsy)] that characterize a broad
415	range of cognitive functions (109). There is a similar need to measure and conceptualize the
416	impact that inflammation has on other psychological functions that impact cognition (e.g.,
417	reward process, aversive process) - there is strong theoretical work and empirical data to support
418	an indirect effect of inflammation on cognition via, for instance, dysregulated reward circuitry
419	that impact performance on cognitive tasks via decreased motivation or increased fatigue (110).
420	Moreover, there are a range of sociodemographic factors that may moderate the association
421	between inflammation and cognition – prior work has found that inflammation and cognition
422	may differ based on age and sex (111, 112). It is reasonable to assume, for instance, that modest
423	increases in inflammation may exert a cumulative effect across the lifespan, and thus may only
424	be detected later in life and/or in specific domains of cognition.

425 **4.4 Anxiety**

RUNNING TITLE: INFLAMMATION, AFFECT, DEPRESSIVE AND ANXIETY DISORDERS AND COGNITIVE TASK PERFORMANCE

426 In the non-genetic analyses, circulating CRP levels was associated with a modestly increased 427 likelihood of meeting criteria for anxiety disorders, although this association was substantially 428 attenuated following adjustments for covariates. Prior research in population-based cohorts have 429 found CRP to associated with an increased risk for anxiety disorders (113, 114), although results 430 are inconsistent and other studies indicate that anxiety prospectively predicts an increase in 431 circulating CRP levels (115). The MR analysis suggests a potential causal role of CRP on any 432 anxiety disorder (which covers a broad range of anxiety-related conditions including panic 433 disorder, social phobia, agoraphobia, GAD). Prior theory has primarily focused on anxiety as a 434 cause of inflammation [see O'Donovan et al. for an excellent review (116)]; however, alternative 435 theories suggest that inflammatory physiology is implicated in both sickness behaviors (e.g., 436 anhedonia, social withdrawal) and anxiety arousal and alarm (117), which would align with the 437 results presented here.

438 **4.5 Limitations**

439 In this study we used a large and broadly representative population-based sample, and we 440 employed a triangulation of methods (non-genetic and genetic analyses) which increases confidence in the inferences drawn. Nevertheless, results should be considered in the context of 441 442 the limitations of the study. First, although broadly representative, like other cohort studies (e.g., 443 UK Biobank), the Lifelines cohort predominantly includes individuals of European descent and 444 is less representative of individuals from low socioeconomic status (118), which consequentially 445 limits the generalizability of findings. Second, analyses were not corrected for multiple 446 comparisons. To check effects are not due to Type 1 errors, there is a need to replicate these 447 findings in other cohorts. Moreover, as effect sizes reported are small and reflect associations in 448 the general population, there is a need for studies to investigate whether there are sub-groups for

RUNNING TITLE: INFLAMMATION, AFFECT, DEPRESSIVE AND ANXIETY DISORDERS AND COGNITIVE TASK PERFORMANCE

449 whom these associations may be larger (e.g., older age, clinical populations). Third, in the 450 genetic analysis the CRP GRS explained 1-4% of the variance in CRP [a level of variance 451 consistent with similar analyses in the ALSPAC cohort (56)] and few cases of depression were 452 observed in Lifelines [although the point prevalence of approximately 4% is consistent with 453 reported population point prevalence estimates (119)]. It is possible that this limited our capacity 454 to detect potential causal effects, were they small in magnitude or non-linear. Fourth, the 455 CogState tasks used in the current study may not be optimal for detecting individual differences 456 in healthy individuals, or even in some conditions such as depression; multiple studies have 457 shown that the CogState tasks used in this study do not improve in successful antidepressant 458 trials, even when improvement in other cognitive measures are observed (120-122). Fifth, 459 although we include multiple instruments related to IL-6 (i.e., genetic variants related to IL-6 and 460 sIL-6R levels), most instruments contain few genetic variants (≤ 3 SNPs) and genetic variants for 461 IL-6 and sIL-6R overlap. While sIL-6R is involved in IL-6 trans-signaling, the overlap of SNPs 462 makes it challenging to interpret the effect of these genetic variants on different immune 463 phenotypes specifically (i.e., IL-6 levels vs IL-6 signaling). Future studies are needed to (1) 464 better understand the biological role of these genetic variants and (2) develop instruments 465 proxying specific IL-6 signaling pathways including IL-6 trans-signaling. Finally, it is worth 466 considering that some instruments in the genetic analyses were associated with potential 467 confounds, although it is unlikely that the small effects observed for some confounds 468 substantially bias parameter estimates.

469 **4.6 Conclusions**

Genetic and non-genetic analyses provide consistent evidence for a modest effect of CRP on
negative affect. Genetic analyses suggest that IL-6 signaling could be relevant for memory, and

RUNNING TITLE: INFLAMMATION, AFFECT, DEPRESSIVE AND ANXIETY DISORDERS AND COGNITIVE TASK PERFORMANCE

- 472 that the association between CRP and anxiety disorders could be causal. Overall, these results
- 473 suggest that inflammation may affect a range of emotional states beyond the cardinal features of
- 474 depression. However, given the small effect sizes and multiple tests conducted, future studies are
- 475 required to investigate whether effects are moderated by sub-groups and whether these findings
- 476 replicate in other cohorts.

RUNNING TITLE: INFLAMMATION, AFFECT, DEPRESSIVE AND ANXIETY DISORDERS AND COGNITIVE TASK PERFORMANCE

477	Funding
478	This work was supported by Harvard University's Mind Brain Behavior Interfaculty
479	Initiative and National Institute of Mental Health grant K23MH132893 (Dr. Mac Giollabhui),
480	and a UK Medical Research Council (MRC) grant to GMK (MC_UU_00032/06) which forms
481	part of the Integrative Epidemiology Unit (IEU) at the University of Bristol. The MRC grant also
482	supports CS and EMF. GMK acknowledges additional funding support from the Wellcome Trust
483	(201486/Z/16/Z and 201486/B/16/Z), MRC (MR/W014416/1; MR/S037675/1; and
484	MR/Z50354X/1), and the UK National Institute of Health and Care Research (NIHR) Bristol
485	Biomedical Research Centre (NIHR 203315). GH and GDS are supported by the MRC
486	(MC_UU_00032/01), and the NIHR Bristol Biomedical Research Centre (NIHR 203315). The
487	views expressed are those of the authors and not necessarily those of the NIHR or the
488	Department of Health and Social Care, UK.

RUNNING TITLE: INFLAMMATION, AFFECT, DEPRESSIVE AND ANXIETY DISORDERS AND COGNITIVE TASK PERFORMANCE

490

Acknowledgments

- 491 The Lifelines initiative has been made possible by subsidy from the Dutch Ministry of
- 492 Health, Welfare and Sport, the Dutch Ministry of Economic Affairs, the University Medical
- 493 Center Groningen (UMCG), Groningen University and the Provinces in the North of the
- 494 Netherlands (Drenthe, Friesland, Groningen). The generation and management of GWAS
- 495 genotype data for the Lifelines Cohort Study is supported by the UMCG Genetics Lifelines
- 496 Initiative (UGLI). UGLI is partly supported by a Spinoza Grant from NWO, awarded to Cisca
- 497 Wijmenga. The authors wish to acknowledge the services of the Lifelines Cohort Study, the
- 498 contributing research centers delivering data to Lifelines, and all the study participants.

RUNNING TITLE: INFLAMMATION, AFFECT, DEPRESSIVE AND ANXIETY DISORDERS AND COGNITIVE TASK PERFORMANCE

500 Conflict of Interest

501 No conflicts of interest were reported.

RUNNING TITLE: INFLAMMATION, AFFECT, DEPRESSIVE AND ANXIETY DISORDERS AND COGNITIVE TASK PERFORMANCE

503Author Contributions

- 504 NMG, GMK, CH and CS conceptualized and designed the study. NMG conducted the non-
- 505 genetic analysis. CS conducted the genetic analyses. NMG and CS wrote the first draft of the
- 506 paper. All authors advised on the project/analysis and critically reviewed the final version of the
- 507 manuscript. CH and GMK provided overall supervision for this project.

508

RUNNING TITLE: INFLAMMATION, AFFECT, DEPRESSIVE AND ANXIETY DISORDERS AND COGNITIVE TASK PERFORMANCE

510

References

511 512	1. Vos T, Lim SS, Abbafati C, Abbas KM, Abbasi M, Abbasifard M, et al. (2020): Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the
512	Global Burden of Disease Study 2019. The Lancet. 396:1204-1222.
514	2. Ferrari AJ, Charlson FJ, Norman RE, Flaxman AD, Patten SB, Vos T, et al. (2013): The
515	epidemiological modelling of major depressive disorder: application for the Global Burden of Disease
516	Study 2010. PLoS One. 8:e69637.
517	3. James SL, Abate D, Abate KH, Abay SM, Abbafati C, Abbasi N, et al. (2018): Global, regional, and
518	national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195
519	countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease
520	Study 2017. The Lancet. 392:1789-1858.
521	4. Taylor CA, Bouldin ED, McGuire LC (2018): Subjective Cognitive Decline Among Adults Aged ≥45
522	Years - United States, 2015-2016. MMWR Morb Mortal Wkly Rep. 67:753-757.
523	5. Janelsins MC, Kesler SR, Ahles TA, Morrow GR (2014): Prevalence, mechanisms, and
524	management of cancer-related cognitive impairment. Int Rev Psychiatry. 26:102-113.
525	6. Ceban F, Ling S, Lui LMW, Lee Y, Gill H, Teopiz KM, et al. (2022): Fatigue and cognitive
526	impairment in Post-COVID-19 Syndrome: A systematic review and meta-analysis. Brain Behav Immun.
527	101:93-135.
528	7. Wang Y, Liu M, Lu Q, Farrell M, Lappin JM, Shi J, et al. (2020): Global prevalence and burden of
529	HIV-associated neurocognitive disorder. A meta-analysis. 95:e2610-e2621.
530	8. Barreira DP, Marinho RT, Bicho M, Fialho R, Ouakinin SRS (2018): Psychosocial and
531	Neurocognitive Factors Associated With Hepatitis C - Implications for Future Health and Wellbeing. Front
532	Psychol. 9:2666.
533	9. Fava M, Mahableshwarkar AR, Jacobson W, Zhong W, Keefe RS, Olsen CK, et al. (2018): What is
534	the overlap between subjective and objective cognitive impairments in MDD? Ann Clin Psychiatry.
535	30:176-184.
536	10. Keefe RS, Harvey PD (2012): Cognitive impairment in schizophrenia. <i>Novel antischizophrenia</i>
537	treatments.11-37.
538	11. Trivedi MH, Rush AJ, Wisniewski SR, Nierenberg AA, Warden D, Ritz L, et al. (2006): Evaluation of
539	outcomes with citalopram for depression using measurement-based care in STAR* D: implications for
540	clinical practice. <i>Am J Psychiatry</i> . 163:28-40.
541	12. Ritchie K, Chan D (2021): The emergence of cognitive COVID. <i>World Psychiatry</i> . 20:52-53.
542	13. Fesharaki-Zadeh A, Lowe N, Arnsten AFT (2023): Clinical experience with the α 2A-adrenoceptor
543	agonist, guanfacine, and N-acetylcysteine for the treatment of cognitive deficits in "Long-COVID19".
544	Neuroimmunology Reports. 3:100154.
545	14. Dowlati Y, Herrmann N, Swardfager W, Liu H, Sham L, Reim EK, et al. (2010): A meta-analysis of
546	cytokines in major depression. <i>Biol Psychiatry</i> . 67:446-457.
547 548	15. Ironson G, Banerjee N, Fitch C, Krause N (2018): Positive emotional well-being, health Behaviors,
548 540	and inflammation measured by C-Reactive protein. <i>Soc Sci Med</i> . 197:235-243.
549 550	16. Felger JC, Treadway MT (2017): Inflammation Effects on Motivation and Motor Activity: Role of Dopamine. <i>Neuropsychopharmacology</i> . 42:216-241.
550	
552	
552	inflammatory biomarkers and depression revisited: systematic review, meta-analysis, and meta- regression. <i>Mol Psychiatry</i> . 26:3302-3314.
555	18. Khandaker GM, Pearson RM, Zammit S, Lewis G, Jones PB (2014): Association of serum
555	interleukin 6 and C-reactive protein in childhood with depression and psychosis in young adult life: a
556	population-based longitudinal study. JAMA Psychiatry. 71:1121-1128.
550	

RUNNING TITLE: INFLAMMATION, AFFECT, DEPRESSIVE AND ANXIETY DISORDERS AND COGNITIVE TASK PERFORMANCE

557 19. Noble JM, Manly JJ, Schupf N, Tang MX, Mayeux R, Luchsinger JA (2010): Association of C-558 reactive protein with cognitive impairment. Arch Neurol. 67:87-92. 559 20. Baune B, Ponath G, Golledge J, Varga G (2008): Association between IL-8 cytokine and cognitive 560 performance in an elderly general population—the MEMO-Study. Neurobiol Aging. 29:937-944. 561 Reichenberg A, Yirmiya R, Schuld A, Kraus T, Haack M, Morag A, et al. (2001): Cytokine-21. 562 associated emotional and cognitive disturbances in humans. Arch Gen Psychiatry. 58:445-452. 563 Singh-Manoux A, Dugravot A, Brunner E, Kumari M, Shipley M, Elbaz A, et al. (2014): Interleukin-22. 564 6 and C-reactive protein as predictors of cognitive decline in late midlife. *Neurology*. 83:486-493. 565 23. Crisan AF, Oancea C, Timar B, Fira-Mladinescu O, Crisan A, Tudorache V (2014): Cognitive 566 impairment in chronic obstructive pulmonary disease. PLoS One. 9:e102468. 567 24. Huang YS, Guilleminault C, Hwang FM, Cheng C, Lin CH, Li HY, et al. (2016): Inflammatory 568 cytokines in pediatric obstructive sleep apnea. Medicine. 95:e4944. 569 Li X, Robertson CM, Yu X, Cheypesh A, Dinu IA, Li J (2014): Early postoperative systemic 25. 570 inflammatory response is an important determinant for adverse 2-year neurodevelopment-associated 571 outcomes after the Norwood procedure. J Thorac Cardiovasc Surg. 148:202-206. 572 Nightingale S, Dreyer AJ, Saylor D, Gisslén M, Winston A, Joska JA (2021): Moving on From 26. 573 HAND: Why We Need New Criteria for Cognitive Impairment in Persons Living With Human 574 Immunodeficiency Virus and a Proposed Way Forward. Clin Infect Dis. 73:1113-1118. 575 27. Mac Giollabhui N (2021): Inflammation and depression: Research designs to better understand 576 the mechanistic relationships between depression, inflammation, cognitive dysfunction, and their 577 shared risk factors. Brain Behav Immun Health. 15:100278. 578 Krogh J, Benros ME, Jorgensen MB, Vesterager L, Elfving B, Nordentoft M (2014): The 28. 579 association between depressive symptoms, cognitive function, and inflammation in major depression. 580 Brain Behav Immun, 35:70-76. 581 29. Goldsmith DR, Haroon E, Woolwine BJ, Jung MY, Wommack EC, Harvey PD, et al. (2016): 582 Inflammatory markers are associated with decreased psychomotor speed in patients with major 583 depressive disorder. Brain Behav Immun. 56:281-288. 584 Mac Giollabhui N, Alloy LB, Hartman CA (2021): Investigating whether depressed youth 30. 585 exhibiting elevated C reactive protein perform worse on measures of executive functioning, verbal 586 fluency and episodic memory in a large, population based sample of Dutch adolescents. Brain Behav 587 Immun. 94:369-380. 588 31. Ribeiro-Santos R, Lucio Teixeira A, Vinicius Salgado J (2014): Evidence for an immune role on 589 cognition in schizophrenia: a systematic review. Curr Neuropharmacol. 12:273-280. 590 Mac Giollabhui N, Swistun D, Murray S, Moriarity DP, Kautz MM, Ellman LM, et al. (2020): 32. 591 Executive dysfunction in depression in adolescence: the role of inflammation and higher body mass. 592 Psychol Med. 50:683-691. 593 33. McAfoose J, Baune BT (2009): Evidence for a cytokine model of cognitive function. *Neurosci* 594 Biobehav Rev. 33:355-366. 595 Carvalho AF, Miskowiak KK, Hyphantis TN, Kohler CA, Alves GS, Bortolato B, et al. (2014): 34. 596 Cognitive dysfunction in depression - pathophysiology and novel targets. CNS Neurol Disord Drug 597 Targets. 13:1819-1835. 598 35. Chesnokova V, Pechnick RN, Wawrowsky K (2016): Chronic peripheral inflammation, 599 hippocampal neurogenesis, and behavior. Brain Behav Immun. 58:1-8. 600 36. Goldsmith D, Bekhbat M, Mehta ND, Felger JC (2023): Inflammation-related functional and 601 structural dysconnectivity as a pathway to psychopathology. *Biol Psychiatry*. 93:405-418. 602 Eisenberger NI, Berkman ET, Inagaki TK, Rameson LT, Mashal NM, Irwin MR (2010): 37. 603 Inflammation-induced anhedonia: endotoxin reduces ventral striatum responses to reward. Biol 604 Psychiatry. 68:748-754.

RUNNING TITLE: INFLAMMATION, AFFECT, DEPRESSIVE AND ANXIETY DISORDERS AND COGNITIVE TASK PERFORMANCE

Brydon L, Harrison NA, Walker C, Steptoe A, Critchley HD (2008): Peripheral Inflammation is
Associated with Altered Substantia Nigra Activity and Psychomotor Slowing in Humans. *Biol Psychiatry*.
607 63:1022-1029.

- 608 39. Harrison NA, Cercignani M, Voon V, Critchley HD (2015): Effects of inflammation on
- 609 hippocampus and substantia nigra responses to novelty in healthy human participants.

610 *Neuropsychopharmacology*. 40:831-838.

- 611 40. Davey Smith G, Ebrahim S (2003): 'Mendelian randomization': can genetic epidemiology
- 612 contribute to understanding environmental determinants of disease? *Int J Epidemiol.* 32:1-22.
- 613 41. Sanderson E, Glymour MM, Holmes MV, Kang H, Morrison J, Munafò MR, et al. (2022): 614 Mendelian randomization. *Nat Rev Methods Primers* 2:6
- 614 Mendelian randomization. *Nat Rev Methods Primers*. 2:6.
- Khandaker GM, Zuber V, Rees JMB, Carvalho L, Mason AM, Foley CN, et al. (2020): Shared
 mechanisms between coronary heart disease and depression: findings from a large UK general
 mechanism based subert. Mal Development 25:1477-1486
- 617 population-based cohort. *Mol Psychiatry*. 25:1477-1486.
- 61843.Perry Bl, Upthegrove R, Kappelmann N, Jones PB, Burgess S, Khandaker GM (2021): Associations619of immunological proteins/traits with schizophrenia, major depression and bipolar disorder: A bi-
- 620 directional two-sample mendelian randomization study. *Brain Behav Immun*. 97:176-185.
- 621 44. Kelly KM, Smith JA, Mezuk B (2021): Depression and interleukin-6 signaling: A Mendelian
 622 Randomization study. *Brain Behav Immun*. 95:106-114.
- 45. Ye Z, Kappelmann N, Moser S, Smith GD, Burgess S, Jones PB, et al. (2021): Role of Inflammation
 in Depression and Anxiety: Tests for Disorder Specificity, Linearity and Potential Causality of Association
 in the UK Biobank. *medRxiv*.
- 46. Hunter CA, Jones SA (2015): IL-6 as a keystone cytokine in health and disease. *Nat Immunol*.
 16:448-457.
- 62847.Rose-John S, Jenkins BJ, Garbers C, Moll JM, Scheller J (2023): Targeting IL-6 trans-signalling:629past, present and future prospects. Nat Rev Immunol. 23:666-681.
- 63048.Crick DC, Khandaker GM, Halligan SL, Burgner D, Mansell T, Fraser A (2023): Comparison of the631stability of glycoprotein acetyls and high sensitivity C-reactive protein as markers of chronic
- 632 inflammation. *Immunology*.
- 63349.Connelly MA, Otvos JD, Shalaurova I, Playford MP, Mehta NN (2017): GlycA, a novel biomarker634of systemic inflammation and cardiovascular disease risk. J Transl Med. 15:1-5.
- 63550.Otvos JD, Shalaurova I, Wolak-Dinsmore J, Connelly MA, Mackey RH, Stein JH, et al. (2015):636GlycA: A Composite Nuclear Magnetic Resonance Biomarker of Systemic Inflammation. Clin Chem.
- 637 61:714-723.
- 638 51. Ritchie Scott C, Würtz P, Nath Artika P, Abraham G, Havulinna Aki S, Fearnley Liam G, et al.
- 639 (2015): The Biomarker GlycA Is Associated with Chronic Inflammation and Predicts Long-Term Risk of
 640 Severe Infection. *Cell Systems*. 1:293-301.
- Kappelmann N, Arloth J, Georgakis MK, Czamara D, Rost N, Ligthart S, et al. (2020): Dissecting
 the Association Between Inflammation, Metabolic Dysregulation, and Specific Depressive Symptoms: A
 Genetic Correlation and 2-Sample Mendelian Randomization Study. JAMA Psychiatry.
- 644 53. Crick DCP, Sanderson E, Jones H, Goulding N, Borges MC, Clayton G, et al. (2023): Glycoprotein
 645 acetyls and depression: Testing for directionality and potential causality using longitudinal data and
 646 Mendelian randomization analyses. J Affect Disord. 335:431-439.
- 64754.Bekkevold O-J, Damås JK, Brumpton BM, Åsvold BO (2023): The causal role of C-reactive protein648and interleukin-6 on anxiety and depression symptoms and life satisfaction: Mendelian randomisation649analyses in the HUNT study. *Psychol Med*.1-8.
- 650 55. Galan D, Perry Bl, Warrier V, Davidson CC, Stupart O, Easton D, et al. (2022): Applying Mendelian 651 randomization to appraise causality in relationships between smoking, depression and inflammation. *Sci*
- 652 *Rep*. 12:15041.

RUNNING TITLE: INFLAMMATION, AFFECT, DEPRESSIVE AND ANXIETY DISORDERS AND COGNITIVE TASK PERFORMANCE

55. Slaney C, Sallis HM, Jones HJ, Dardani C, Tilling K, Munafo MR, et al. (2023): Association between inflammation and cognition: Triangulation of evidence using a population-based cohort and Mendelian randomization analyses. *Brain Behav Immun*. 110:30-42.

Fragoni P, Korologou-Linden RS, Howe LD, Davey Smith G, Ben-Shlomo Y, Stergiakouli E, et al.
(2022): Causal effects of circulating cytokine concentrations on risk of Alzheimer's disease and cognitive
function. *Brain Behav Immun.* 104:54-64.

- 65958.Fleshner M, Frank M, Maier SF (2017): Danger Signals and Inflammasomes: Stress-Evoked Sterile660Inflammation in Mood Disorders. Neuropsychopharmacology. 42:36-45.
- 66159.Slavich GM (2020): Social safety theory: a biologically based evolutionary perspective on life662stress, health, and behavior. Annu Rev Clin Psychol. 16.
- 663 60. Murphy K, Weaver C (2017): *Janeway's Immunobiology (9th Edition)*. New York, New York: 664 Garland Science, Taylor & Francis Group.
- 665 61. Kiecolt-Glaser JK, Derry HM, Fagundes CP (2015): Inflammation: depression fans the flames and 666 feasts on the heat. *Am J Psychiatry*. 172:1075-1091.
- 667 62. Miller AH, Raison CL (2016): The role of inflammation in depression: from evolutionary
 668 imperative to modern treatment target. *Nat Rev Immunol*. 16:22-34.
- 669 63. Slavich GM, Irwin MR (2014): From stress to inflammation and major depressive disorder: a 670 social signal transduction theory of depression. *Psychol Bull*. 140:774-815.
- 671 64. Scholtens S, Smidt N, Swertz MA, Bakker SJ, Dotinga A, Vonk JM, et al. (2015): Cohort Profile: 672 LifeLines, a three-generation cohort study and biobank. *Int J Epidemiol*. 44:1172-1180.
- 673 65. Sijtsma A, Rienks J, van der Harst P, Navis G, Rosmalen JGM, Dotinga A (2021): Cohort Profile 674 Update: Lifelines, a three-generation cohort study and biobank. *Int J Epidemiol*. 51:e295-e302.
- 675 66. Ross TP (2014): The reliability and convergent and divergent validity of the Ruff Figural Fluency 676 Test in healthy young adults. *Arch Clin Neuropsychol*. 29:806-817.
- 677 67. Ruff RM, Light RH, Evans RW (1987): The Ruff Figural Fluency Test: a normative study with 678 adults. *Dev Neuropsychol*. 3:37-51.
- 679 68. Kuiper JS, Oude Voshaar RC, Verhoeven FE, Zuidema SU, Smidt N (2017): Comparison of
 680 cognitive functioning as measured by the Ruff Figural Fluency Test and the CogState computerized
 681 battery within the LifeLines Cohort Study. *BMC psychology*. 5:1-12.
- 682 69. Gulpers B, Lugtenburg A, Zuidersma M, Verhey F, Voshaar RO (2018): Anxiety disorders and 683 figural fluency: A measure of executive function. *J Affect Disord*. 234:38-44.
- Mac Giollabhui N, Alloy LB, Schweren LJS, Hartman CA (2021): Investigating whether a
 combination of higher CRP and depression is differentially associated with worse executive functioning
 in a cohort of 43,896 adults. *Brain Behav Immun.* 96:127-134.
- 687 71. Overbeek T, Schruers K, Griez E (1999): MINI: Mini international neuropsychiatric interview,
 688 Dutch version 5.0. 0 (DSM-IV). *Maastricht: University of Maastricht*.
- 689 72. Hergueta T, Weiller E (2017): *MINI-S for DSM-5, Dutch version*.
- 690 73. Lecrubier Y, Sheehan D, Weiller E, Amorim P, Bonora I, Sheehan K, et al. (1997): The Mini
- International Neuropsychiatric Interview (MINI). A short diagnostic structured interview: Reliability and
 validity according to the CIDI. *Eur Psychiatry*. 12:224-231.
- 693 74. Wanders RB, van Loo HM, Vermunt JK, Meijer RR, Hartman CA, Schoevers RA, et al. (2016):
 694 Casting wider nets for anxiety and depression: disability-driven cross-diagnostic subtypes in a large
 695 cohort. *Psychol Med.* 46:3371-3382.
- 69675.Watson D, Clark LA, Tellegen A (1988): Development and validation of brief measures of positive697and negative affect: the PANAS scales. J Pers Soc Psychol. 54:1063.
- 698 76. Crawford JR, Henry JD (2004): The Positive and Negative Affect Schedule (PANAS): Construct
- validity, measurement properties and normative data in a large non-clinical sample. *Br J Clin Psychol*.
 43:245-265.

RUNNING TITLE: INFLAMMATION, AFFECT, DEPRESSIVE AND ANXIETY DISORDERS AND COGNITIVE TASK PERFORMANCE

701 77. Team RC (2021): R: A language and environment for statistical computing. Vienna, Austria: R 702 Foundation for Statistical Computing,. 703 78. Hemani G, Elsworth B, Palmer T, Rasteiro R (2024): ieugwasr: Interface to the 'OpenGWAS' 704 Database API. R package version 0.2.2-9000. https://github.com/MRCIEU/ieugwasr. 705 Said S, Pazoki R, Karhunen V, Võsa U, Ligthart S, Bodinier B, et al. (2022): Genetic analysis of over 79. 706 half a million people characterises C-reactive protein loci. Nat Commun. 13:2198. 707 Collaboration IRGCERF, Sarwar N, Butterworth AS, Freitag DF, Gregson J, Willeit P, et al. (2012): 80. 708 Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies. 709 Lancet. 379:1205-1213. 710 Swerdlow DI, Holmes MV, Kuchenbaecker KB, Engmann JE, Shah T, Sofat R, et al. (2012): The 81. 711 interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation 712 analysis. Lancet. 379:1214-1224. 713 Rosa M, Chignon A, Li Z, Boulanger MC, Arsenault BJ, Bosse Y, et al. (2019): A Mendelian 82. 714 randomization study of IL6 signaling in cardiovascular diseases, immune-related disorders and longevity. 715 NPJ Genom Med. 4:23. 716 Project IOG (2023): Glycoprotein acetyls Dataset: met-d-GlycA. 83. Prins BP, Abbasi A, Wong A, Vaez A, Nolte I, Franceschini N, et al. (2016): Investigating the 717 84. 718 Causal Relationship of C-Reactive Protein with 32 Complex Somatic and Psychiatric Outcomes: A Large-719 Scale Cross-Consortium Mendelian Randomization Study. PLoS Med. 13:e1001976. 720 85. Swerdlow DI, Kuchenbaecker KB, Shah S, Sofat R, Holmes MV, White J, et al. (2016): Selecting 721 instruments for Mendelian randomization in the wake of genome-wide association studies. Int J 722 *Epidemiol.* 45:1600-1616. 723 86. Machiela MJ, Chanock SJ (2015): LDlink: a web-based application for exploring population-724 specific haplotype structure and linking correlated alleles of possible functional variants. *Bioinformatics*. 725 31:3555-3557. 726 87. Myers TA, Chanock SJ, Machiela MJ (2020): LDlinkR: An R Package for Rapidly Calculating Linkage 727 Disequilibrium Statistics in Diverse Populations. Frontiers in Genetics. 11. 728 Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, et al. (2007): PLINK: a tool 88. 729 set for whole-genome association and population-based linkage analyses. Am J Hum Genet. 81:559-575. 730 89. Aulchenko YS, De Koning D-J, Haley C (2007): Genomewide rapid association using mixed model 731 and regression: a fast and simple method for genomewide pedigree-based quantitative trait loci 732 association analysis. Genetics. 177:577-585. 733 Kleiber C, Zeileis A (2008): Applied econometrics with R. Springer Science & Business Media. 90. 734 91. Burgess S, Thompson SG (2011): Avoiding bias from weak instruments in Mendelian 735 randomization studies. Int J Epidemiol. 40:755-764. 736 92. Slavish DC, Jones DR, Smyth JM, Engeland CG, Song S, McCormick NM, et al. (2020): Positive and 737 Negative Affect and Salivary Markers of Inflammation Among Young Adults. Int J Behav Med. 27:282-738 293. 739 Brouwers C, Mommersteeg PM, Nyklíček I, Pelle AJ, Westerhuis BL, Szabó BM, et al. (2013): 93. 740 Positive affect dimensions and their association with inflammatory biomarkers in patients with chronic 741 heart failure. Biol Psychol. 92:220-226. 742 94. Sepah SC, Bower JE (2009): Positive affect and inflammation during radiation treatment for 743 breast and prostate cancer. Brain Behav Immun. 23:1068-1072. 744 Stellar JE, John-Henderson N, Anderson CL, Gordon AM, McNeil GD, Keltner D (2015): Positive 95. 745 affect and markers of inflammation: discrete positive emotions predict lower levels of inflammatory 746 cytokines. Emotion. 15:129. 747 96. Lin C, Michopoulos V, Powers A, Wingo AP, Schwartz A, Bradley B, et al. (2018): Affect, 748 inflammation, and health in urban at-risk civilians. J Psychiatr Res. 104:24-31.

RUNNING TITLE: INFLAMMATION, AFFECT, DEPRESSIVE AND ANXIETY DISORDERS AND COGNITIVE TASK PERFORMANCE

- P3. Boylan JM, Lewis TT, Coe CL, Ryff CD (2015): Educational Status, Anger, and Inflammation in the
 MIDUS National Sample: Does Race Matter? *Ann Behav Med.* 49:570-578.
- Milaneschi Y, Kappelmann N, Ye Z, Lamers F, Moser S, Jones PB, et al. (2021): Association of
 inflammation with depression and anxiety: evidence for symptom-specificity and potential causality
 from UK Biobank and NESDA cohorts. *Mol Psychiatry*. 26:7393-7402.
- 754 99. Milaneschi Y, Lamers F, Berk M, Penninx B (2020): Depression Heterogeneity and Its Biological 755 Underpinnings: Toward Immunometabolic Depression. *Biol Psychiatry*. 88:369-380.
- Felger JC, Haroon E, Miller AH (2018): What's CRP got to do with it? Tackling the complexities of
 the relationship between CRP and depression. *Brain Behav Immun.* 73:163-164.
- Mac Giollabhui N, Ellman LM, Coe CL, Byrne ML, Abramson LY, Alloy LB (2020): To exclude or not
 to exclude: Considerations and recommendations for C-reactive protein values higher than 10 mg/L. *Brain Behav Immun.* 87:898-900.
- 761 102. Wium-Andersen MK, Ørsted DD, Nielsen SF, Nordestgaard BG (2013): Elevated C-Reactive
- 762 Protein Levels, Psychological Distress, and Depression in 73 131 Individuals. *JAMA Psychiatry*. 70:176.
- 763 103. Khandaker GM, Zuber V, Rees JM, Carvalho L, Mason AM, Foley CN, et al. (2019): Shared
- mechanisms between coronary heart disease and depression: findings from a large UK general
 population-based cohort. *Mol Psychiatry*.1-10.
- 766104.Consortium I-RMRA (2012): The interleukin-6 receptor as a target for prevention of coronary767heart disease: a mendelian randomisation analysis. The Lancet. 379:1214-1224.
- Collaboration CRPCHDG (2011): Association between C reactive protein and coronary heart
 disease: mendelian randomisation analysis based on individual participant data. *BMJ*. 342.
- Foley ÉM, Slaney C, Donnelly NA, Kaser M, Ziegler L, Khandaker GM (2024): A novel biomarker of
 interleukin 6 activity and clinical and cognitive outcomes in depression. *Psychoneuroendocrinology*.
 164:107008.
- 773107.Zainal NH, Newman MG (2022): Depression and worry symptoms predict future executive774functioning impairment via inflammation. *Psychol Med.* 52:3625-3635.
- Mac Giollabhui N, Foster S, Lowry CA, Mischoulon D, Raison CL, Nyer M (2022): Interleukin-6
 receptor antagonists in immunopsychiatry: Can they lead to increased interleukin-6 in the central
 and use an unit of the central for the ce
- nervous system (CNS) and worsening psychiatric symptoms? *Brain Behav Immun*. 103:202-204.
- 778109.Boogert NJ, Madden JR, Morand-Ferron J, Thornton A (2018): Measuring and understanding779individual differences in cognition. Philos Trans R Soc Lond B Biol Sci. 373.
- 110. Mac Giollabhui N, Mischoulon D, Dunlop BW, Kinkead B, Schettler PJ, Liu RT, et al. (2023):
- 781 Individuals with depression exhibiting a pro-inflammatory phenotype receiving omega-3
- polyunsaturated fatty acids experience improved motivation-related cognitive function: Preliminary
 results from a randomized controlled trial. *Brain Behav Immun Health*. 32:100666.
- 111. Klein SL, Flanagan KL (2016): Sex differences in immune responses. *Nat Rev Immunol*. 16:626638.
- 786 112. Ferrucci L, Fabbri E (2018): Inflammageing: chronic inflammation in ageing, cardiovascular
 787 disease, and frailty. *Nat Rev Cardiol*. 15:505-522.
- 788113.Vogelzangs N, Beekman ATF, de Jonge P, Penninx BWJH (2013): Anxiety disorders and789inflammation in a large adult cohort. *Transl Psychiatry*. 3:e249-e249.
- Total 114. Costello H, Gould RL, Abrol E, Howard R (2019): Systematic review and meta-analysis of the
 association between peripheral inflammatory cytokines and generalised anxiety disorder. *BMJ open*.
 9:e027925.
- 793 115. Glaus J, von Känel R, Lasserre AM, Strippoli MPF, Vandeleur CL, Castelao E, et al. (2018): The
- bidirectional relationship between anxiety disorders and circulating levels of inflammatory markers:
- results from a large longitudinal population-based study. *Depress Anxiety*. 35:360-371.

RUNNING TITLE: INFLAMMATION, AFFECT, DEPRESSIVE AND ANXIETY DISORDERS AND COGNITIVE TASK PERFORMANCE

- 796 116. O'Donovan A, Slavich GM, Epel ES, Neylan TC (2013): Exaggerated neurobiological sensitivity to
- threat as a mechanism linking anxiety with increased risk for diseases of aging. *Neurosci Biobehav Rev.*37:96-108.
- Raison CL, Miller AH (2017): Pathogen-host defense in the evolution of depression: insights into
 epidemiology, genetics, bioregional differences and female preponderance. *Neuropsychopharmacology*.
 42:5-27.
- Klijs B, Scholtens S, Mandemakers JJ, Snieder H, Stolk RP, Smidt N (2015): Representativeness of
 the LifeLines Cohort Study. *PLoS One*. 10:e0137203.
- 804 119. Vos T, Lim SS, Abbafati C, Abbas KM, Abbasi M, Abbasifard M, et al. (2020): Global burden of 369
 805 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global
 806 Burden of Disease Study 2019. *The Lancet*. 396:1204-1222.
- 807 120. Freeman MP, Cheng LJ, Moustafa D, Davies A, Sosinsky AZ, Wang B, et al. (2017): Vortioxetine
- for major depressive disorder, vasomotor, and cognitive symptoms associated with the menopausal
 transition. *Ann Clin Psychiatry*. 29:249-257.
- 810 121. Mahableshwarkar AR, Zajecka J, Jacobson W, Chen Y, Keefe RS (2015): A randomized, placebo-
- controlled, active-reference, double-blind, flexible-dose study of the efficacy of vortioxetine on cognitive
 function in major depressive disorder. *Neuropsychopharmacology*. 40:2025-2037.
- 813 122. Olver JS, Ignatiadis S, Maruff P, Burrows GD, Norman TR (2008): Quetiapine augmentation in
- 814 depressed patients with partial response to antidepressants. *Hum Psychopharmacol*. 23:653-660.

Figure 1. Associations of genetic risk scores for inflammatory markers with mood, anxiety disorders and positive and negative affect scores.





Figure 2. Associations of genetic risk scores for inflammatory markers with cognitive task performance.



na cog	nition in the Lifelines Cohort	CRP Levels	CRP <i>cis</i> Genetic Risk Score
	Major Depressive Disorder	1	
	Any Depressive Disorder	1	†
••	Generalised Anxiety Disorder	1	1
Mood	Any Anxiety Disorder	1	t
Disorder/ Affect	Negative Affect	1	t
	Positive Affect	Ļ	1
	Executive Function	↓ I	1
a particular	Attention (RT)	1	Ţ
	Psychomotor speed (RT)	1	Å
ognition	Episodic memory		÷
	Working memory	÷	÷

Figure 3. Visualisation of the overall pattern of results for CRP in the cohort and genetic analyses.

Arrows indicate direction of effect. Solid arrows (p < .05), dashed arrows (p > .05).

Positive arrows = increased liability to mood disorder/affect and better cognitive performance, except for reaction time (RT) measures where positive score = higher RT (i.e., slower response). All mood disorder measures are from Baseline assessment where sample size is largest. Non-genetic results = adjusted analysis.

Marker	Author of GWAS/	Sample	Outcome	SNPs	SNPs available on		
	Instrument	size		Identified			
					each chip		
Primary	analysis						
CRP	(Said et al., 2022)	575,531	Circulating CRP	19	16		
IL-6R	(Ahluwalia et al., 2021)	52,654	Circulating IL-6	2	2		
	(Sarwar et al., 2012)	27,185	Circulating IL-6	1	1		
sIL6R	(Rosa et al., 2019)	3,301	Circulating sIL6R	34	34		
GlycA	(Borges, 2020)	115,078	Circulating GlycA	87	73-74		
Secondar	y analysis						
CRP	(Said et al., 2022)	575,531	Circulating CRP	485	445-446		
IL-6	(Ahluwalia et al., 2021)	52,654	Circulating IL-6	3	2-3		
CRP = C-	reactive protein; IL-6 = inte	erleukin-6,	IL-6R = IL-6 receptor,	sIL6R = solu	ble IL-6R		

Table 1. Large available genome-wide association studies and previous publications used to identify single nucleotide polymorphisms associated with systemic inflammatory markers.

Measures	Cohort Analyses	Genetic Analyses
	<u>(n = 147,815)</u>	<u>(n = 58,713)</u>
Baseline Assessment		
Age [Mean (SD)]	44.52 (13.12)	43.04 (13.56)
	n = 147,815	n = 58,713
Sex (% Female)	59 %	60%
	n = 147,815	n = 58,695
Education (N %)	n = 146,050	n = 58,112
- Lower	43,750 (30%)	16,359
- Moderate	57,785 (40%)	23,770
- Higher	44,515 (30%)	17,983
Body mass index	26.05 (4.34)	25.81 (4.27)
	n = 147,719	n = 58,680
RFFT (Unique designs) [Mean (SD)]	81.50 (22.94)	82.46 (23.01)
	n = 88,096	n = 36,563
Any Depressive Disorder (Current Major Depression or	3.4%	2.9%
Dysthymia)	n = 141,045	n = 56,861
Major Depressive Episode (Current)	2.1%	1.8%
	n = 141,538	n = 57,048
Any Anxiety Disorder (panic disorder, agoraphobia, social	7.8%	7.2%
phobia, or GAD)	n = 141,538	n = 57,048
Generalized Anxiety Disorder	4.2%	3.8%
	n = 141,539	n = 57,048
Negative Affect Score [Mean (SD)]	20.71 (13.12)	20.70 (5.22)

Table 2 I fals **a** 1 . . • .• ... 1 - 4 E - 11

	n = 139,217	n = 57,964
Positive Affect Score [Mean (SD)]	35.37 (4.25)	35.37 (4.19)
	n = 139,217	n = 57,964
C-reactive protein level (mg/L), [Median (IQR),	1.2 (.60, 2.80),	1.2 (2.2)
Mean (SD)]	2.61 (4.76)	2.62 (4.60)
	n = 55,098	n = 23,607
First follow up		
Any Depressive Disorder (Current Major Depression or	4.1%	Not used
Dysthymia)	n = 77,758	
Major Depressive Episode (Current)	3.0%	Not used
	n = 77,758	
Any Anxiety Disorder (panic disorder, agoraphobia, social	8.3%	Not used
phobia, or GAD)	n = 77,758	
Generalized Anxiety Disorder	5.9%	Not used
	n = 77,758	
Cogstate: Episodic Memory (Accuracy), Mean (SD)	0.96 (0.12)	0.96 (0.12)
	n = 84,819	n = 36,798
Cogstate: Working Memory (Accuracy), Mean (SD)	1.31 (0.19)	1.32 (0.19)
	n = 83,721	n = 36,363
Cogstate: Visual Attention (Response Time), Mean (SD)	2.69 (0.09)	2.68 (0.09)
	n = 82,175	n = 35,743
	2.56 (0.16)	2.55 (0.16)
Cogstate: Psychomotor Speed (Response Time), Mean (SD)	2.50 (0.10)	× ,

Lower = no education, primary education, lower/preparatory vocational education, lower general secondary education; Moderate = intermediate vocational education/apprenticeship, higher secondary education; Higher = higher vocational education, university; IQR = Inter Quartile Range.

Table 3. Bivariate Correlations of Study Variables for 147,815 Participants

Measure	2.	3.	4.	5.	6.	7.	8.	9.	10.	11.	12.	13.	14.	15.	16.	17.	18.	19.	20.	21.
1. T1 CRP (log-transformed)	-0.03	-0.03	0.04	0.03	-0.07	0.04	0.03	0.03	-0.05	0.03	0.14	0.11	0.36	0.10	0.03	0.03	0.03	0.03	0.02	0.03
2. T2 Episodic Memory ^B	-	0.31	-0.16	-0.16	0.21	-0.02	-0.03	-0.05	-0.02	-0.19	0.01	0.22	-0.08	-0.04	-0.02	-0.01	-0.03	-0.03	-0.01	-0.01
3. T2 Working Memory ^B		-	-0.17	-0.17	0.20	-0.02	-0.02	-0.04	$.00^{a}$	-0.20	01 ^a	-0.2	-0.07	-0.04	-0.02	0	-0.03	-0.02	-0.01	-0.01
4. T2 Psychomotor Speed ^C			-	0.63	-0.30	.01 ^a	.00 ^a	0.04	$.00^{a}$	0.39	$.00^{a}$	0.21	0.08	0.04	0.01	-0.02	0.01	0	-0.01	-0.02
5. T2 Visual Attention ^C				-	-0.34	0.01	.00 ^a	0.05	-0.02	0.43	-0.01	0.20	0.09	0.05	0.02	-0.01	0.02	0.01	0.01	-0.01
6. T1 RFFT					-	-0.04	-0.02	-0.07	-0.07	-0.32	0.03	-0.35	-0.11	-0.08	-0.04	-0.01	-0.04	-0.02	-0.02	0.01
7. T1 Depression						-	0.25	0.27	-0.2	-0.02	0.05	0.07	0.04	0.07	0.35	0.19	0.8	0.21	0.40	0.18
8. T2 Depression							-	0.21	-0.13	-0.05	0.03	0.05	0.03	0.05	0.20	0.41	0.22	0.83	0.21	0.42
9. T1 Negative Affect								-	-0.21	-0.05	0.17	0.08	-0.01	0.06	0.32	0.26	0.25	0.17	0.30	0.22
10. T1 Positive Affect									-	-0.02	-0.01	-0.1	-0.02	-0.02	-0.17	-0.13	-0.18	-0.1	-0.18	-0.11
11. T1 Age										-	-0.04	0.23	0.19	0.09	-0.01	-0.06	-0.01	-0.04	-0.04	-0.06
12. T1 Female											-	0.02	-0.06	0.03	0.07	0.07	0.04	0.03	0.05	0.06
13. T1 Education												-	0.17	0.08	0.06	0.03	0.07	0.05	0.04	0.02
14. T1 Body mass index													-	0.13	0.03	0.01	0.04	0.03	0.02	0.01
15. T1 Health Status														-	0.07	0.04	0.06	0.05	0.05	0.04
16. T1 ANX															-	0.28	0.31	0.17	0.72	0.2
17. T2 ANX																-	0.17	0.37	0.22	0.84
18. T1 MDE																	-	0.20	0.38	0.16
19. T2 MDE																		-	0.17	0.40
20. T1 GAD																			-	0.21
21. T2 GAD																				-

medRxiv preprint doi: https://doi.org/10.1101/2024.04.17.24305950; this version posted April 19, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

Table 4. Associations of CRP levels with affect, depressive and anxiety disorders, and cognitive task performance in the Lifelines cohort Please note: point estimates do not include 95% confidence intervals (and N, p-value) as we do not currently have access to the Lifelines Cohort Workspace, the Cohort will allow us access to data for response to reviewer comments, we will add these (p-value, 95% CI, N) as necessary during review.

Theeessary				Baselir	ne			Follow-up									
Predictors	MDD	Any DEP	GAD	Any ANX	Negative Affect	Positive Affect	RFFT	MDD	Any DEP	GAD	Any ANX	Psycho motor Speed	Attention	Episodic Memory	Working Memory		
	Odd's Ratio Standardized regression coefficient								Odd's	Ratio		Standardized regression coefficient					
						Mode	l 1 (Una	djusted	analysis)								
CRP ^a	1.59	1.57	1.24	1.29	.03	05	07	1.43	1.42	1.26	1.22	.03	.03	03	03		
				М	odel 2 (Adjı	usted for a	ge, sex,	educatio	on, healt	h status,	and BMI)					
CRP ^a	1.02†	1.22	1.01†	1.06†	.01	04	03	1.06†	1.07†	1.05†	1.03†	.01	.01	0†	01†		
Age	.98	.98	.98	.99	06	0†	24	.97	.97	.97	.98	.38	.38	14	17		
Female	1.53	1.59	1.56	1.66	.17	0†	.04	1.28	1.33	1.58	1.6	.01†	.01†	0†	01		
Education: High	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref		
Education: Moderate	1.62	1.76	1.3	1.28	.04	04	19	1.39	1.31	1.1†	1.12	.07	.07	13	08		
Education: Low	2.94	3.02	1.64	1.72	.11	11	35	2.16	1.84	1.26	1.3	.16	.16	22	18		
Health Status: O Dx	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref		
Health Status: 1 Dx	1.83	1.64	1.55	1.43	.04	01	02	1.5	1.5	1.36	1.29	0†	0†	0†	01†		
Health Status: 2 Dx	2.97	2.63	2.26	1.82	.04	0†	02	2.5	2.34	1.67	1.47	0†	0†	01	02		
Health Status: 3+ Dx	4.24	3.76	2.82	2.65	.02	01	01	3.71	3.28	2	1.67	0†	0†	01	0†		
BMI	1.04	1.03	1.01	1.01	0†	0†	0†	1.05	1.04	1.02	1.02	0†	0†	03	01†		
CRP = C-react	tive Prote	in; MDD	= Major D	epressive	Disorder; Any	/ DEP = MD	D or Dyst	hymia; G	AD = Gene	eralized Ar	xiety Diso	rder; Any AN	X = panic dis	order, agorap	hobia,		

social phobia, or GAD; RFFT = Ruff Figural Fluency Test; $a = \log$ -transformed variable; BMI = Body Mass Index; Ref = Reference Category for categorical variables; + p > .05; Odds ratios are reported in logistic regression predicting binary outcomes and standardized beta coefficients are reported for linear regression; For values $\leq .001$ and $\geq .001$, values were rounded to 0.